pegfilgrastim

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Mar 1, 2006 → Mar 1, 2008

NCT ID

NCT00364468

About pegfilgrastim

pegfilgrastim is a phase 2 stage product being developed by Kyowa Kirin for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00364468. Target conditions include Neutropenia.

What happened to similar drugs?

8 of 18 similar drugs in Neutropenia were approved

Approved (8) Terminated (5) Active (8)

✅MicafunginAstellas PharmaApproved

✅Imipenem + ImipenemMerckApproved

✅Ceftolozane-Tazobactam + MeropenemMerckApproved

✅Ceftolozane-tazobactam IVMerckApproved

✅Neulasta (pegfilgrastim)AmgenApproved

✅Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved

✅FilgrastimSandoz GroupApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03993639	Phase 2	Completed	May 28, 2019	Aug 28, 2020	Peripheral Blood Stem Cell Transplantation
NCT00364468	Phase 2	Completed	Mar 1, 2006	Mar 1, 2008	Neutropenia

Competing Products

20 competing products in Neutropenia

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	39
HHPG-19K Injection	Jiangsu Hengrui Medicine	Phase 3	32
caspofungin acetate + Comparator: AmBisome	Merck	Phase 2	35
Imipenem + Imipenem	Merck	Approved	43
Posaconazole IV solution + Posaconazole powder for oral suspension	Merck	Phase 1	29
Ceftolozane-Tazobactam + Meropenem	Merck	Approved	50
Ceftolozane-tazobactam IV	Merck	Approved	35
Daptomycin + Daptomycin	Merck	Phase 3	32
pegfilgrastim	Amgen	Phase 3	40
Neulasta (pegfilgrastim)	Amgen	Approved	43
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)	Gilead Sciences	Approved	35
Filgrastim Hospira (US) + US-approved Neupogen®	Pfizer	Phase 1	29
HSP-130 + US-approved Neulasta + EU-approved Neulasta	Pfizer	Phase 1	29
linezolid + vancomycin	Pfizer	Phase 3	40
Anidulafungin	Pfizer	Phase 1/2	32
Nivestim®	Pfizer	Pre-clinical	18
Antibacterial agent for the treatment of febrile neutropenia	Pfizer	Pre-clinical	26
Voriconazole	Pfizer	Phase 1/2	32
Filgrastim Hospira (US) + U.S.-approved Neupogen®	Pfizer	Phase 1	29
ciprofloxacin + cefepime	Bayer	Phase 3	37